Decoding biology demands a bold approach
Recursion's TechBio approach: The future of AI drug discovery
In traditional drug discovery, 90% of drugs fail in clinical trials, after more than a decade in development and ~$2 billion in costs.
We’re changing the paradigm – leading with data, AI, and an industrialized approach to dramatically improve the cost, timeline, and probability of success of developing new medicines — because patients are waiting.
Recursion’s competitive advantage
A robust pipeline of AI-enabled first-in-class & best-in-class assets
As a top AI drug discovery and development platform company, our advanced preclinical and clinical-stage drug development programs are focused on areas of high unmet need across oncology and rare diseases.
.svg)
>50 petabytes of high-quality, multimodal data
Utilizing AI in pharma and biotech, we’ve generated and aggregated one of the
world’s largest relatable biological and chemical datasets across phenomics,
transcriptomics, proteomics, ADME, and de-identified patient data for our drug
development platform.
.svg)
BioHive-2, the most powerful supercomputer in pharma
Built in partnership with NVIDIA, BioHive-2 ranks as the 76th most powerful
supercomputer by the Top500 list in 2025.
.svg)
Leading industry partners
We are leveraging partnerships with Big Pharmas and leading tech companies to expand our therapeutic reach, scale and improve our AI drug discovery and development platform, and drive new discoveries.
Data is the differentiator… and scale matters
Unlike traditional drug discovery, which begins with a specific target or
hypothesis, we leverage the Recursion OS — our drug discovery and
development platform for AI in pharma connects technical and scientific tools
spanning physical experimentation to in silico analysis. This next generation
biotech drug discovery and development platform, along with >50 petabytes ofhigh-quality multimodal data allows us to train machine learning models that can help us identify promising new targets and design highly optimized molecules that will become potential first-in-class and best-in-class medicines. Combined with hundreds of thousands of de-identified patient records from our partners Tempus and Helix, all of these data layers are connected in the Recursion OS, which is continuously learning and improving in a “virtuous cycle” feedback loop.
Faster discovery, better medicines
Instead of evaluating a few programs over years to find a “hit,” our drug discovery and development platform allows us to evaluate hundreds of potential programs, and quickly funnel those into the most promising opportunities. We then use our precision chemistry platform to design the best chemical compounds for synthesis in our automated lab. With this system, we’re able to identify hit candidates in weeks, instead of years, and for thousands of dollars as opposed to millions.
Explore our pipeline
